Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
US-2024101580-A1 · Mar 28, 2024 · US
Derivatives of 1-amino-2-cyclobutylethylboronic acid
US9771381B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9771381-B2 |
| Application number | US-201414153752-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 13, 2014 |
| Priority date | Sep 29, 2008 |
| Publication date | Sep 26, 2017 |
| Grant date | Sep 26, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound selected from or a pharmaceutically acceptable salt or boronic acid anhydride thereof. 2. The compound of claim 1 , which is or a pharmaceutically acceptable salt or boronic acid anhydride thereof.
Assignees
Inventors
Classifications
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title
specific for metastasis · CPC title
Antineoplastic agents · CPC title
specific for leukemia · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9771381B2 cover?
- The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
- Who is the assignee on this patent?
- Millennium Pharm Inc
- What technology area does this patent fall under?
- Primary CPC classification C07F5/025. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 26 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).